Mirtazapine Smelttab Viatris (Mirtazapine)

Mirtazapine works by blocking central presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonises postsynaptic 5‑HT2 and 5‑HT3 receptors and strongly blocks histamine H1 receptors. This combined receptor activity enhances neurotransmission in brain pathways that regulate mood and produces a sedative effect that can aid sleep.

The appropriate dose is determined individually by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage may be started at a low level and titrated upward as needed, but exact strength and regimen should follow the prescriber’s written order and local prescribing guidelines. No generic dosing information is provided here.

Safety data for mirtazapine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the risk‑benefit profile with the patient and consider alternative therapies if appropriate. Breastfeeding mothers should consult a physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any temperature requirements), and assists with import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in greater sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss. Unlike tricyclic antidepressants, it has fewer anticholinergic and cardiac side effects. However, individual response varies, and clinicians choose the agent based on symptom profile, comorbidities, and tolerability.

Mirtazapine Smelttab Viatris tablets should be stored at temperatures below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging is tightly closed. Do not store in a bathroom or near heat sources. Follow any additional handling instructions provided by the supplier to maintain product stability.

The medication is taken orally, usually once daily in the evening due to its sedative properties. Tablets should be swallowed whole with a glass of water and may be taken with or without food, as directed by the prescriber. Patients should not crush, chew, or split the tablets unless specifically instructed, and they should follow the dosing schedule prescribed to achieve optimal therapeutic effect.

Although uncommon, serious adverse reactions can include agranulocytosis, severe neutropenia, hepatic dysfunction, and rare cases of Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should be monitored for signs of infection, unexplained fever, jaundice, or severe skin reactions and seek immediate medical attention if these occur. Additionally, any emergence of suicidal thoughts, especially during the initial treatment phase, warrants urgent evaluation.

Mirtazapine is contraindicated in patients who have a known hypersensitivity to the drug or any of its excipients. It should also be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs) or who have used an MAOI within the past 14 days due to the risk of hypertensive crisis. Caution is advised for patients with severe hepatic impairment, uncontrolled cardiovascular disease, or a history of seizures, and the prescriber should assess suitability before initiating therapy.